Industry News
Virtual Colonoscopy Just As Good For Seniors As Standard Procedure
Feb 28, 2012
A new study led by a doctor from the Mayo Clinic in Arizona in the US, finds that "virtual colonoscopy", known more formally as computerized tomographic CT colonography, is comparable to standard colonoscopy for people aged 65 and over. The American College of Radiology Imaging Network study was published online before print on 23 February in the journal Radiology... Read More
Virtual Colonoscopy Just As Good For Seniors As Standard Procedure
Feb 28, 2012
A new study led by a doctor from the Mayo Clinic in Arizona in the US, finds that "virtual colonoscopy", known more formally as computerized tomographic CT colonography, is comparable to standard colonoscopy for people aged 65 and over. The American College of Radiology Imaging Network study was published online before print on 23 February in the journal Radiology... Read More
Giving Patients Bad News - Training Evaluated
Feb 27, 2012
A recent issue of the Journal of Cancer Education reports on the experience of medical students who participated in videotaped sessions to practice conveying difficult news to "standardized patients" (SPs) by role-playing patients with different types of cancers who received bad medical news... Read More
When PTEN Suppresses Brain Tumors Or Not - New Understanding
Feb 27, 2012
Scientists at the University of Dundee have gained new insight into the working of an important tumor suppressor, called PTEN, which is involved in at least a quarter of all cancers. Their study, published in Science Signaling, discovered that when 'turned off' or damaged PTEN drives the development of many cancers. The team, led by Dr... Read More
Leukemia Patients Who Do Not Respond To Interferon Benefit From Imatinib
Feb 27, 2012
A new study has found that patients with chronic myeloid leukemia (CML) who have not responded to interferon treatments experience long-term benefits when they switch to the targeted drug imatinib. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the study indicates that imatinib is the treatment of choice for these patients... Read More
Study Could Lead To Novel Therapy For Cancer
Feb 27, 2012
In a study published in Nature Medicine, Loyola researchers report on a promising new technique that potentially could turn immune system killer T cells into more effective weapons against infections and possibly cancer. The technique involves delivering DNA into the immune system's instructor cells... Read More
With A Newly Developed Math Equation, New Insights Could Come On Cell Development And Drug Therapies
Feb 27, 2012
Neither births nor deaths stop the flocking of organisms. They just keep moving, says theoretical physicist John J. Toner of the University of Oregon. The notion, he says, has implications in biology and eventually could point to new cancer therapies... Read More
New Study Will Enable Better Antenatal Diagnosis For Sufferers Of Rare Blood And Skeletal Disorder
Feb 27, 2012
Researchers have identified an elusive gene responsible for Thrombocytopenia with Absent Radii (TAR), a rare inherited blood and skeletal disorder. As a result, this research is now being transformed into a medical test that allows prenatal diagnosis and genetic counselling in affected families... Read More
Blood Mystery Solved
Feb 27, 2012
You probably know your blood type: A, B, AB or O. You may even know if you're Rhesus positive or negative. But how about the Langereis blood type? Or the Junior blood type? Positive or negative? Most people have never even heard of these. Yet this knowledge could be "a matter of life and death," says University of Vermont biologist Bryan Ballif... Read More
Leukemia Patients Who Do Not Respond To Interferon Benefit From Imatinib
Feb 27, 2012
A new study has found that patients with chronic myeloid leukemia (CML) who have not responded to interferon treatments experience long-term benefits when they switch to the targeted drug imatinib. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the study indicates that imatinib is the treatment of choice for these patients... Read More
Previous Page Next Page